Studies of Methionine-PET and PBR28-PET in Brain Metastases to Differentiate Tumor Recurrence and Radiation Necrosis Following Stereotactic Radiosurgery

Status: Terminated
Location: See location...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

The goal of this protocol is to evaluate the potential of PET imaging of amino acid transport and microglial activation to improve the differentiation of tumor recurrence and radiation necrosis in patients with brain metastases after treatment with stereotactic radiosurgery (SRS) who have re-growing lesions. These state-of-the-art imaging tools will be used in combination with standard magnetic resonance imaging (MRI), MR spectroscopy (MRS) and FDG-PET (fluorodeoxyglucose).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: No
View:

• Patients over 18 years with brain metastases from melanoma or non-small cell lung cancer

• Patients must have had SRS and regrowth in at least one lesion > 0.5 cm in greatest dimension and fall into one of two categories: a) patient is deemed clinically appropriate for surgical intervention (biopsy or craniotomy) OR b) patient is asymptomatic and has a life expectancy of > 6 months so that serial follow-up imaging is appropriate

• Willingness to participate in imaging studies

• Able to give informed consent

Locations
United States
Connecticut
Yale University
New Haven
Time Frame
Start Date: January 2015
Completion Date: June 27, 2017
Participants
Target number of participants: 8
Treatments
Melanoma Brain Metastases
Stage 4 cancer patient population with melanoma with brain metastases previously treated with SRS
Lung Cancer Brain Metastases
Stage 4 cancer patient population with non-small cell lung cancer with brain metastases previously treated with SRS
Related Therapeutic Areas
Sponsors
Leads: Yale University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials